Meningococcal vaccine groups A B C Y W-135 conjugate - GlaxoSmithKline

Drug Profile

Meningococcal vaccine groups A B C Y W-135 conjugate - GlaxoSmithKline

Alternative Names: MenABCWY; Meningococcal ABCWY Vaccine; rMenB + MenACWY

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer GlaxoSmithKline
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 13 Feb 2018 GlaxoSmithKline completes a phase II trial in Meningococcal group A, B, C, W-135 and Y infections (In children, In adults, In adolescents, Prevention) in Poland and Finland (IM) (NCT02946385)
  • 02 Feb 2018 Phase II development for Meningococcal group A, B, C, W-135, Y infections (In adolescents, Prevention) is ongoing in Chile, Colombia, Finland, Panama, Poland and USA (IM) (GlaxoSmithKline pipeline, February 2018)
  • 26 Oct 2016 Efficacy data from a phase IIb trial in Meningococcal group B vaccine presented at IDWeek 2016 (IDW-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top